• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

    5/29/25 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KNSA alert in real time by email

    LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will present at the following investor conferences in June:

    • Jefferies 2025 Global Healthcare Conference on Thursday, June 5 at 12:50 p.m. Eastern Time
    • Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10 at 8:00 a.m. Eastern Time – Fireside Chat

    A live webcast of Kiniksa's presentations will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the events will also be available on Kiniksa's website within approximately 48 hours after the event.

    About Kiniksa

    Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa's portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

    Every Second Counts! ®

    Kiniksa Investor & Media Contact

    Jonathan Kirshenbaum

    (781) 829-3949

    [email protected]



    Primary Logo

    Get the next $KNSA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KNSA

    DatePrice TargetRatingAnalyst
    9/29/2025$60.00Buy
    TD Cowen
    3/13/2025$40.00Buy
    Citigroup
    9/13/2024$40.00Buy
    Jefferies
    5/3/2024$34.00Overweight
    Wells Fargo
    12/29/2021$37.00 → $34.00Buy
    B of A Securities
    More analyst ratings

    $KNSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

    LONDON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in fireside chats at the following investor conferences in September: Citi 2025 Biopharma Back to School Summit on Wednesday, September 3 at 9:00 a.m. Eastern Time2025 Wells Fargo Healthcare Conference on Thursday, September 4 at 9:30 a.m. Eastern Time A live webcast of Kiniksa's presentations will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the events will also be available on Kiniksa's website within approximately 48 hours after the event. About KiniksaKiniksa is a biop

    8/28/25 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $625 - $640 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis initiated; Phase 2 data expected in 2H 2026 –– Cash balance increased by $39.4 million in Q2 2025 to $307.8 million –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today

    7/29/25 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025

    LONDON, July 24, 2025 (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time to report its second quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and regis

    7/24/25 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Kiniksa Pharmaceuticals with a new price target

    TD Cowen initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $60.00

    9/29/25 9:58:02 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

    Citigroup initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    3/13/25 7:43:42 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Kiniksa Pharmaceuticals with a new price target

    Jefferies initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/13/24 7:34:05 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF OPERATING OFFICER Tessari Eben exercised 42,000 units of Class A Ordinary Share at a strike of $17.92 and sold $1,609,860 worth of Class A Ordinary Share (42,000 units at $38.33) (SEC Form 4)

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    10/1/25 4:44:52 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF OPERATING OFFICER Tessari Eben exercised 6,500 units of Class A Ordinary Share at a strike of $8.83 and sold $597,976 worth of Class A Ordinary Share (16,400 units at $36.46), decreasing direct ownership by 22% to 34,552 units (SEC Form 4)

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    9/17/25 4:45:48 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF OPERATING OFFICER Tessari Eben exercised 98,660 units of Class A Ordinary Share at a strike of $15.51 and sold $3,506,278 worth of Class A Ordinary Share (98,660 units at $35.54) (SEC Form 4)

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    9/8/25 4:38:47 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    SEC Filings

    View All

    SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

    144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    9/3/25 4:56:49 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

    144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    9/3/25 4:16:39 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

    9/3/25 7:35:17 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Financials

    Live finance-specific insights

    View All

    Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $625 - $640 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis initiated; Phase 2 data expected in 2H 2026 –– Cash balance increased by $39.4 million in Q2 2025 to $307.8 million –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today

    7/29/25 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025

    LONDON, July 24, 2025 (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time to report its second quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and regis

    7/24/25 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, w

    4/29/25 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/14/24 4:32:31 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/14/24 4:15:22 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/13/24 4:30:25 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care